ROR1 and neoplasm: A phase I clinical study (NCT02706392) from Fred Hutchinson Cancer Research Center was designed to assess the safety and anti-tumor effects of autologous anti-ROR1 CAR-T cells transplanted into patients with advanced, ROR1-positive, stage IV NSCLC [41].